Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 20, 2021 4:23pm
131 Views
Post# 33242277

RE:Ed Nash just incriminated himself...

RE:Ed Nash just incriminated himself...

I thought it was as part of the discussion about getting data out as fast as possible, that he knew this to be the case and was essentially urging Paul to release data ASAP. Paul seemed to confirm summer (my expectation late summer) for safety and efficacy afterwards. I think he talked about a couple of data points in regard to efficacy, I think all he's talking about there is the first tumour shrinkages and then follow on scans that confirm the first findings, maybe something that rises to the level of Partial Response, that's a more meaningful finding. That seems to be how it works with other biotech. It sounds like once they think they have something solid they will go public not too much delay.


Wino115 wrote: I don't think he realized his comment on how he needs to focus more on oncology (paraphrase) because in unmet needs, small improvements have huge financial implications showed either his inexperience or inability to look forward and be proactive (or laziness).  A decent analysts already knows this -- it's obvious if you know the industry.  We've been yelling about that for a few months now! He shoudl be embarassed. 

 

<< Previous
Bullboard Posts
Next >>